Inogen, Inc. (NASDAQ:INGN - Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 665,900 shares, a decline of 16.6% from the January 31st total of 798,600 shares. Approximately 3.2% of the shares of the company are short sold. Based on an average daily trading volume, of 246,200 shares, the days-to-cover ratio is currently 2.7 days.
Wall Street Analyst Weigh In
INGN has been the topic of several analyst reports. StockNews.com lowered shares of Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a report on Wednesday, February 26th.
View Our Latest Report on Inogen
Inogen Stock Down 0.6 %
Inogen stock traded down $0.05 on Friday, hitting $7.76. The company's stock had a trading volume of 398,512 shares, compared to its average volume of 318,805. The firm has a market cap of $205.87 million, a P/E ratio of -3.45 and a beta of 1.15. The company has a fifty day moving average price of $10.13 and a 200-day moving average price of $10.01. Inogen has a one year low of $6.14 and a one year high of $13.33.
Institutional Investors Weigh In On Inogen
Institutional investors and hedge funds have recently bought and sold shares of the business. Royce & Associates LP boosted its stake in shares of Inogen by 499.7% in the 4th quarter. Royce & Associates LP now owns 311,199 shares of the medical technology company's stock valued at $2,854,000 after purchasing an additional 259,308 shares in the last quarter. Prudential Financial Inc. boosted its stake in shares of Inogen by 141.5% in the 4th quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company's stock valued at $3,301,000 after purchasing an additional 210,961 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Inogen by 154.8% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 263,561 shares of the medical technology company's stock valued at $2,417,000 after purchasing an additional 160,106 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Inogen by 312.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company's stock valued at $1,694,000 after purchasing an additional 132,287 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Inogen by 25.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock valued at $5,574,000 after purchasing an additional 123,208 shares in the last quarter. Institutional investors own 89.94% of the company's stock.
Inogen Company Profile
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
